Using FL-261 Radionuclide Imaging to Diagnose and Stage Advanced Cancers Including Lung, Colorectal, and Head & Neck Tumors

What this Trial Is About

Researchers are evaluating a new imaging agent called FL-261, which targets a protein called c-MET that is often found in higher amounts in several cancers such as non-small cell lung cancer, colorectal cancer, and head and neck cancer. This protein is linked to tumor growth and resistance to treatment. The study aims to assess the safety, how the agent spreads in the body, and its ability to detect tumors. It also compares imaging results to the presence of c-MET in tissue samples to explore its diagnostic value. Participants will undergo diagnostic imaging using either 68GaGa-FL-261 PET or 111InIn-FL-261 SPECT scans. These imaging methods aim to highlight tumors by targeting c-MET. Some patients may also have standard 18FFDG PET scans for comparison. The study involves collecting clinical data and lab tests such as blood, urine, and ECG within a week before and after imaging. Tumor confirmation is done by tissue analysis or ongoing follow-up. During the study, images will be reviewed independently by nuclear medicine experts to evaluate diagnostic accuracy and tumor targeting. Participants general health and safety will be monitored throughout. Researchers will measure the diagnostic performance of the imaging agents over one year and assess their correlation with c-MET expression in tumor tissues. The study does not involve treatment but focuses on improving cancer diagnosis and staging.

FL-261 Imaging for Cancer Diagnosis and Staging